目的 探討脾氨肽口服凍干粉聯(lián)合膦甲酸鈉治療帶狀皰疹的臨床療效。方法 選取2020年10月—2022年10月資陽市第一人民醫(yī)院收治的96例帶狀皰疹患者，隨機分為對照組（48例）和治療組（48例）。對照組患者靜脈靜點膦甲酸鈉氯化鈉注射液，250 mL/次，1次/d。在對照組的基礎(chǔ)上，治療組口服脾氨肽口服凍干粉，4 mg/次，1次/d。兩組用藥7 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀改善時間，視覺模擬疼痛（VAS）評分，血清炎性因子白細(xì)胞介素-6（IL-6）、干擾素-γ（IFN-γ）、β-內(nèi)啡肽（β-EP）和血漿P物質(zhì)（SP）水平，及不良反應(yīng)情況。結(jié)果 治療后，治療組患者臨床有效率（97.92%）明顯高于對照組（81.25%，P＜0.05）。治療后，治療組癥狀改善時間均早于對照組（P＜0.05）。治療后3、7 d，兩組疼痛VAS評分均較治療前明顯降低（P＜0.05），且治療組明顯低于對照組（P＜0.05）。治療后，兩組IL-6、SP水平均明顯低于治療前，而IFN-γ、β-EP水平均高于治療前（P＜0.05），且治療組IL-6、SP、IFN-γ和β-EP水平均明顯好于對照組（P＜0.05）。治療后，治療組不良反應(yīng)發(fā)生率為6.25%，明顯低于對照組（14.58%，P＜0.05）。結(jié)論 膦甲酸鈉聯(lián)合脾氨肽口服凍干粉治療帶狀皰疹患者療效確切，可有效降低疼痛，機體炎性反應(yīng)改善良好，且安全有效。

Objective To investigate the clinical efficacy of Spleen Aminopeptide Oral Lyophilized Powder combined with foscarnet sodium in treatment of herpes zoster. Methods Patients (96 cases) with herpes zoster in Ziyang First People's Hospital from October 2020 to October 2022 were randomly divided into control (48 cases) and treatment (48 cases) group. Patients in the control group were iv administered with Foscarnet Sodium and Sodium Chloride Injection, 250 mL/time, once daily. Patients in the treatment group were po administered with Spleen Aminopeptide Oral Lyophilized Powder on the basis of the control group, 4 mg/time, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, and the relief time of symptom, the VAS scores the levels of IL-6, SP, IFN-γ and β-EP, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.92%) was significantly higher than that of the control group (81.25%, P < 0.05). After treatment, the improvement time of symptoms in the treatment group was earlier than that in the control group (P < 0.05). On the 3rd and 7th day after treatment, the VAS score of pain in both groups was significantly lower than that before treatment, and the pain score in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the levels of IL-6 and SP in two groups were significantly lower than those before treatment, while the levels of IFN-γ and β-EP were higher, and which in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group (6.25%) was significantly lower than that in the control group (14.58%, P < 0.05). Conclusion Spleen Aminopeptide Oral Lyophilized Powder combined with foscarnet sodium in treatment of herpes zoster is effective in treatment of patients with herpes zoster, and can effectively reduce pain and improve organic inflammatory response, which is safe and effective.

R971

資陽市科技計劃項目（Zykjjsc20-2018-14）